Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

被引：0
|
作者：
Lindholm, Daniel E. [1 ,2 ]
Licciardi, Paul, V [1 ,2 ]
Ratu, Felisita T. [1 ]
Mulholland, E. Kim [1 ,3 ]
Nguyen, Cattram D. [1 ,4 ]
Russell, Fiona M. [1 ,2 ]
机构：
[1] Murdoch Childrens Res Inst MCRI, Infect & Immun, Melbourne, Vic, Australia
[2] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia
[3] London Sch Hyg & Trop Med, London, England
[4] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia
来源：
VACCINE | 2020年 / 38卷 / 33期
关键词：
Pneumococcal conjugate vaccine; Poor antibody persistence; Ethnicity; Reduced-dose schedule; Fiji; Infant; NASOPHARYNGEAL CARRIAGE; POLYSACCHARIDE VACCINE; IMMUNE-RESPONSES; CHILDREN; IMPACT;
D O I：
10.1016/j.vaccine.2020.06.025
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5095 / 5099
页数：5
相关论文
共 50 条
  • [1] Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants
    Choo, S
    Zhang, QB
    Seymour, L
    Akhtar, S
    Finn, A
    JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (04): : 1260 - 1263
  • [2] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China
    Zhu, Fengcai
    Hu, Yuemei
    Li, Jingxin
    Ye, Qiang
    Young, Mariano M., Jr.
    Zhou, Xin
    Chen, Zhangjing
    Yan, Bing
    Liang, John Z.
    Gruber, William C.
    Giardina, Peter C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (09) : 999 - 1010
  • [3] Persistence of IgG Antibody Following Routine Infant Immunization with the 7-Valent Pneumococcal Conjugate Vaccine
    Grant, Lindsay R.
    Burbidge, Polly
    Haston, Mitch
    Johnson, Marina
    Reid, Raymond
    Santosham, Mathuram
    Goldblatt, David
    O'Brien, Katherine L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (05) : E138 - E142
  • [4] Immunisation with a pneumococcal 7-valent conjugate vaccine
    Dagan, R
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (04) : 287 - 291
  • [5] Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age
    Russell, F. M.
    Carapetis, J. R.
    Burton, R. L.
    Lin, J.
    Licciardi, P. V.
    Balloch, A.
    Tikoduadua, L.
    Waqatakirewa, L.
    Cheung, Y. B.
    Tang, M. L. K.
    Nahm, M. H.
    Mulholland, E. K.
    VACCINE, 2011, 29 (03) : 535 - 544
  • [6] Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
    Russell, F. M.
    Licciardi, P. V.
    Balloch, A.
    Biaukula, V.
    Tikoduadua, L.
    Carapetis, J. R.
    Nelson, J.
    Jenney, A. W. J.
    Waqatakirewa, L.
    Colquhoun, S.
    Cheung, Y. B.
    Tang, M. L. K.
    Mulholland, E. K.
    VACCINE, 2010, 28 (18) : 3086 - 3094
  • [7] Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine
    Quinet, Beatrice
    Laudat, France
    Gurtman, Alejandra
    Patterson, Scott
    Sidhu, Mohinder
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (10) : 1065 - 1076
  • [8] Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
    van Deursen, Anna M. M.
    van Mens, Suzan P.
    Sanders, Elisabeth A. M.
    Vlaminckx, Bart J. M.
    de Melker, Hester E.
    Schouls, Leo M.
    de Greeff, Sabine C.
    van der Ende, Arie
    EMERGING INFECTIOUS DISEASES, 2012, 18 (11) : 1729 - 1737
  • [9] Safety & Immunologic Non-inferiority of 13-valent Pneumococcal Conjugate Vaccine Compared to 7-valent Pneumococcal Conjugate Vaccine Given with Routine Vaccines in Healthy Infants
    Kieninger, D. M.
    Kueper, K.
    Steul, K.
    Juergens, C.
    Ahlers, N.
    Baker, S.
    Giardina, P.
    Gruber, W.
    Scott, D.
    VACCINE, 2008,
  • [10] Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar™):: Primary dosing series in healthy Chinese infants
    Li, Rong Cheng
    Li, Feng Xiang
    Li, Yan Ping
    Guo, Su Ying
    Nong, Y.
    Ye, Qiang
    Fang, Kong Xiong
    Wei, Shao Chao
    Wang, Zhiqian
    Lockhart, Stephen
    VACCINE, 2008, 26 (18) : 2260 - 2269
12345